Sermorelin
Sermorelin Acetate
Regulatory Status
A compounded peptide with prior pharmaceutical history and evolving FDA treatment.
FDA · Updated Apr 2026
Generally treated as research-only outside licensed channels.
MHRA · Updated Apr 2026
Prescription-only context where available.
TGA · Updated Apr 2026
Growth-hormone-related peptide class remains restricted in sport.
WADA · Updated Apr 2026
Overview
Sermorelin is a growth-hormone-releasing hormone analog discussed in endocrine and body-composition research. It has a longer clinical history than many peptides grouped into the current compounding debate, which is part of why it appears often in reclassification coverage.
Research Snapshot
- Primarily studied for growth hormone signaling
- Often compared with CJC-1295 and tesamorelin
- Human data exists, but current commercial positioning still varies by market
Regulatory Context
In the US, sermorelin sits inside the broader FDA discussion around compounded peptides and category treatment. Outside the US it is more commonly framed as prescription-only or research-only depending on the jurisdiction.
Continue Reading
Readers also explore
CJC-1295
CJC-1295 with Drug Affinity Complex
growth hormone optimisation · body composition · sleep quality
Open profileIpamorelin
Ipamorelin Acetate
growth hormone release · muscle growth · fat loss
Open profileTesamorelin
Tesamorelin
Visceral fat research · Metabolic signaling
Open profile